ATE223435T1 - Verfahren zur diagnose von störungen durch bestimmung der expression von gage- tumorabstossungsantigen-vorläufern - Google Patents

Verfahren zur diagnose von störungen durch bestimmung der expression von gage- tumorabstossungsantigen-vorläufern

Info

Publication number
ATE223435T1
ATE223435T1 AT94923463T AT94923463T ATE223435T1 AT E223435 T1 ATE223435 T1 AT E223435T1 AT 94923463 T AT94923463 T AT 94923463T AT 94923463 T AT94923463 T AT 94923463T AT E223435 T1 ATE223435 T1 AT E223435T1
Authority
AT
Austria
Prior art keywords
tumor rejection
rejection antigen
antigen precursors
expression
determining
Prior art date
Application number
AT94923463T
Other languages
English (en)
Inventor
Den Eynde Benoit Van
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE223435T1 publication Critical patent/ATE223435T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
AT94923463T 1993-07-22 1994-07-13 Verfahren zur diagnose von störungen durch bestimmung der expression von gage- tumorabstossungsantigen-vorläufern ATE223435T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9603993A 1993-07-22 1993-07-22
US08/250,162 US5610013A (en) 1993-07-22 1994-05-27 Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
PCT/US1994/007878 WO1995003422A1 (en) 1993-07-22 1994-07-13 Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors

Publications (1)

Publication Number Publication Date
ATE223435T1 true ATE223435T1 (de) 2002-09-15

Family

ID=22254881

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94923463T ATE223435T1 (de) 1993-07-22 1994-07-13 Verfahren zur diagnose von störungen durch bestimmung der expression von gage- tumorabstossungsantigen-vorläufern

Country Status (14)

Country Link
US (1) US5610013A (de)
EP (1) EP0711355B1 (de)
JP (1) JP3641692B2 (de)
KR (1) KR100281178B1 (de)
CN (1) CN1059465C (de)
AT (1) ATE223435T1 (de)
AU (1) AU677687B2 (de)
CA (1) CA2167692C (de)
DE (1) DE69431301T2 (de)
FI (1) FI960268A7 (de)
NO (1) NO960158L (de)
NZ (1) NZ269435A (de)
TW (1) TW498104B (de)
WO (1) WO1995003422A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648226A (en) * 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US5858689A (en) * 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US6939707B2 (en) * 1993-07-22 2005-09-06 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode GAGE genes and uses thereof
AU727028B2 (en) * 1996-06-25 2000-11-30 Ludwig Institute For Cancer Research Brain glycogen phosphorylase cancer antigen
DK0970206T3 (da) 1997-01-27 2008-10-13 Ludwig Inst Cancer Res Lage-1-tumorassocierede nukleinsyrer
US5879892A (en) 1997-04-25 1999-03-09 Ludwig Institute For Cancer Research Leukemia associated genes
WO1999028502A1 (en) * 1997-11-28 1999-06-10 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcription in vivo
US5905145A (en) * 1998-03-06 1999-05-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode TAGE molecules, and uses thereof
US6245525B1 (en) 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US7001999B1 (en) 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
AU3753499A (en) * 1998-04-20 1999-11-08 Paul B. Fisher Colon cancer-associated antigens and their diagnostic and therapeutic uses
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6509172B1 (en) 1998-09-30 2003-01-21 Ludwig Institute For Cancer Research Isolated, truncated nucleic acid which are members of the gage, and uses thereof
CN1402782A (zh) 1999-10-19 2003-03-12 路德维哥癌症研究院 Mage－a12抗原肽及其应用
EP1259545A2 (de) 2000-01-21 2002-11-27 Ludwig Institute For Cancer Research Mit dem "nicht-kleine-zellen" lungenkrebs assoziierte antigene und deren verwendung
EP1605045A3 (de) * 2000-02-15 2006-03-01 Curagen Corporation Polypeptide und dafür kodierende Nukleinsäure
WO2001061009A2 (en) * 2000-02-15 2001-08-23 Curagen Corporation Polypeptides and nucleic acids encoding same
US7470428B2 (en) 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
AU2003270311A1 (en) * 2002-09-06 2004-03-29 Mannkind Corporation Epitope sequences
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
AU2004249254B2 (en) * 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
CN101057145B (zh) * 2004-06-23 2014-10-22 得克萨斯系统大学评议会 使用双粒子复合体检测生物分子的方法和组合物
PL1833506T3 (pl) * 2004-12-29 2016-01-29 Mannkind Corp Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych
JP2008526763A (ja) * 2004-12-29 2008-07-24 マンカインド コーポレイション 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法
SG162817A1 (en) 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
EP3238782A3 (de) * 2010-04-06 2018-01-03 ExoCyte Therapeutics Pte, LTD Verfahren zur behandlung von karzinomen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105538A (en) * 1977-01-21 1978-08-08 Mattox William J Process for the refining of used motor oils and products thereof
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
DE4238416A1 (de) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen

Also Published As

Publication number Publication date
FI960268A0 (fi) 1996-01-19
JPH09504165A (ja) 1997-04-28
FI960268L (fi) 1996-01-19
AU677687B2 (en) 1997-05-01
FI960268A7 (fi) 1996-01-19
NO960158D0 (no) 1996-01-15
CA2167692A1 (en) 1995-02-02
EP0711355A1 (de) 1996-05-15
TW498104B (en) 2002-08-11
NO960158L (no) 1996-01-22
CN1059465C (zh) 2000-12-13
EP0711355A4 (de) 1998-05-06
EP0711355B1 (de) 2002-09-04
DE69431301D1 (de) 2002-10-10
AU7332294A (en) 1995-02-20
DE69431301T2 (de) 2003-07-31
KR100281178B1 (ko) 2001-04-02
NZ269435A (en) 1997-11-24
US5610013A (en) 1997-03-11
CN1127532A (zh) 1996-07-24
JP3641692B2 (ja) 2005-04-27
CA2167692C (en) 2009-07-07
WO1995003422A1 (en) 1995-02-02

Similar Documents

Publication Publication Date Title
ATE223435T1 (de) Verfahren zur diagnose von störungen durch bestimmung der expression von gage- tumorabstossungsantigen-vorläufern
DE69531866D1 (de) Isoliertes nukleinsäuremolekül, das für den tumorabstossungs-antigenvorläufer dage kodiert und seine verwendung
EP0711173A4 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
DE69535214D1 (de) Verfahren zur diagnose des glaukoms
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
DE69020376D1 (de) Verfahren zur Herstellung von Mono- oder Dicarbonsäure-Stoffen, die durch langkettige Kohlenwasserstoffe substituiert sind.
DE60041818D1 (de) Gereinigtes antigen für die alzheimer krankheit und verfahren zu dessen herstellung und verwendung
DE3866558D1 (de) Verfahren zur herstellung von 1,1,1-trifluor-2,2-dichloraethan durch hydrofluorierung in gegenwart von katalysatoren.
EP1361229A3 (de) Verwendung von Tyrosine Kinase (PYK2) zur Produktion von Antikörper
ATE234858T1 (de) Isolierte und verkürzte nukleinsäuremoleküle kodierend für gage-tumorabstossungsantigen
DE3583564D1 (de) Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
ATE39249T1 (de) Verfahren zur herstellung von polyisocyanatopolyisocyanuraten durch katalytische cyclotrimerisierung von polyisocyanaten.
DE69729954D1 (de) Identifizierungsverfahren für Substanzen die an das Pyk2 Polypeptid binden
DE3865678D1 (de) Satz und verfahren zur diagnose der iga-nephropathie.
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
DE3681033D1 (de) Katalytisches verfahren zur herstellung von fluoraomatischen verbindungen mittels n-sek-alkylpyridiniumsalze.
ATE127478T1 (de) Onkogen kodierendes polypeptid, das wachstumsfaktoraktivität besitzt, verfahren zu seiner herstellung und verwendung.
DK0495907T3 (da) cDNA-fragment, som koder for alfa-interferon-receptorgenet, og fremgangsmåde til fremstilling af et tilsvarende protein
DE3777596D1 (de) Verfahren zur herstellung von 2-nitro-5-phenoxy-n-alkylsulfonylbenzamiden durch nitrierung.
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
PT914417E (pt) Dnase ii humana
DE58904746D1 (de) Antikoerper, verfahren zu ihrer herstellung, klone zur erzeugung der antikoerper sowie verwendung der antikoerper zur diagnose und therapie von tumoren.
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
ATE90793T1 (de) Antikoerper, verfahren zu ihrer herstellung, klone zur erzeugung der antikoerper sowie verwendung der antikoerper zur diagnose und therapie von tumoren.
ATE86503T1 (de) Verfahren zur spezifischen diagnose von amyloidosen sowie die dazugehoerige substanz.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties